BGHL (EUR): Estimated NAV(s)     BOUSSARD

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
66
BGHL (EUR): Estimated NAV(s)

 

 

BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares

The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.

 

Close of business 31/03/2017.

 

Estimated NAV

 

  Euro Shares Sterling Shares
Estimated NAV €  22.6054 £  19.8607
Estimated MTD return  -0.06 %  -0.06 %
Estimated YTD return  2.08 %  2.16 %
Estimated ITD return  126.05 %  98.61 %

 

NAV and returns are calculated net of management and performance fees

 

 

For further information please contact:

 

Boussard & Gavaudan Investment Management, LLP.

Emmanuel Gavaudan +44 (0) 20 3751 5389       Email    : info@bgam-uk.com

 

The Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the "Shares") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.

This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute, or form part of, any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.

Neither the Company nor BG Fund ICAV has been, and neither will be, registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"). Consequently any such securities may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.

You should always bear in mind that:

all investment is subject to risk;

results in the past are no guarantee of future results;

the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; and

if you are in any doubt about the contents of this communication or if you consider making an investment decision, you are advised to seek expert financial advice.

 

This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.

 

 

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...03463799f3

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DAN, GPRO, PSNL Deals Under Investor Scrutiny

Updated Category News Views 40

Behind the Curtain: What Do These Deals Mean for Shareholders? Sometimes, investing in a stock ain't just about numbers on a screen—it's about untangling the whole messy ball of yarn these companies hand you with a smile. We're looking at Dana Incorporated (NYSE: DAN), GoPro, Inc. (NASDAQ: GPRO), and Personalis, Inc. (NASDAQ: PSNL). They've all got deals on the table,...

Continue Reading
Raytron Dominates Global Thermal Imaging Market in 2026

Updated Category News Views 106

Raytron's Market Supremacy: By the Numbers If you're looking at the thermal imaging sector and wondering what's what, take a clue from Raytron. This outfit isn't just playing the game—it's running the show with a staggering 30% of the global market in 2025. That's right, they hold the medal for leading global shipments in thermal imaging, and unlike many industries...

Continue Reading
Asphalt Additives Market Set for $7.07B Boom by 2031

Updated Category News Views 65

Asphalt Additives: A Lucrative Growth Path Let me tell you, the asphalt additives market isn't just sticking to the roads; it's rolling out real potential. Heading for a $7.07B finish line by 2031 with a steady pace of 7.3% CAGR, it's a road worth staking your claims on. The underlying story? It's more than just laying tar. Pavement to Profit: Key Drivers The asphalt...

Continue Reading
Pearl Meyer Leaders Grab NACD's Coveted Governance Honor

Updated Category News Views 26

NACD Recognition for Governance Grit Some folks just know how to steer a ship, and that's exactly what Pearl Meyer's Matt Turner and Jannice Koors have been doing. This year, they made it onto the NACD's 2026 Directorship 100 list, swinging as heavy hitters in the Governance Professionals category. It's not just another day at the office when you're honored by the...

Continue Reading
Epson Unveils Early Black Friday Tech Deals

Updated Category News Views 69

Diving Headfirst into Holiday Tech Splurging The holiday hustle is upon us, folks, and Epson's stepping up with early Black Friday deals that'll have tech heads scrambling. They’re cutting prices up to $250 on their swanky home lineup—projectors, printers, scanners, you name it. This ain't just about making someone else smile, though; it's about the sweet spot where...

Continue Reading
Doximity's Legal Woes: Class Action Deadline Looms

Updated Category News Views 15

The Truth Behind Doximity's Promises The brass tacks of investing often boil down to trust—a commodity that's now in short supply over at Doximity, Inc. (NYSE: DOCS). Investors have been left hanging after promises of lucrative engagement signals turned out to be a mere pipe dream. Levi & Korsinsky, LLP sounds the alarm on what's shaping up to be a high-stakes class...

Continue Reading
Insulin Delivery Devices: A Billion-Dollar Surge

Updated Category News Views 20

When's the last time you saw a medical device market promising a $10 billion leap in under five years? Yeah, the insulin delivery devices market's got that kind of upside, projected to skyrocket from $16.92 billion in 2026 to a whopping $26.37 billion by 2031. That's a 9.3% annual growth rate. The numbers and the stakes are both staggering. Regional and Segment Leaders...

Continue Reading
Peanuts and Diabetes: A Surprising Health Link

Updated Category News Views 68

A Nutty Approach to Diabetes Prevention Who would've thought peanuts could pack such a punch against diabetes? Amid the usual suspects of healthy foods, it's these humble legumes that are making headlines. The Peanut Institute, backed by fresh research, is shining a spotlight on their potential role in preventing type 2 diabetes, a disease that's affecting roughly 40...

Continue Reading
Terra-Gen's $950M Lockhart Facility Powers California

Updated Category News Views 128

A New Giant in California's Solar Landscape Out in California's desert, Terra-Gen has flipped the switch on something pretty colossal: the $950 million Lockhart Solar and Storage Project. Picture this—a solar beast boasting 538.7 MW of capacity, primed to light up around 350,000 homes and businesses. That's not just flipping a light switch; that's sparking a fire that...

Continue Reading
Defense Contractors Push Forward Amid Indictments

Updated Category News Views 18

The Big Names Hold Steady Defense contractors are showing off their shiny earnings just as some disturbing headlines shake things up. It's like they're putting their best foot forward to steady the ship while the waters get choppy with terrorism charges and all sorts of geopolitical noise. Follow the smart money to see where the true bets are being placed—it all unfolds...

Continue Reading

Top 5 Most Recently Viewed Articles

Twilio's Q4 Results Spark Diverse Analyst Reactions

Updated Category News Views 232

Twilio Inc Fourth Quarter Overview Twilio Inc reported notable financial results for the fourth quarter, capturing the attention of several analysts within the market. The company’s performance has sparked diverse reactions, particularly regarding its future guidance and the evolving role of artificial intelligence within its operations. Market Response to Q4 Earnings...

Continue Reading
FHLBank Indianapolis Dividends for Second Quarter of 2025

Updated Category News Views 180

FHLBank Indianapolis Declares Second Quarter Dividends FHLBank Indianapolis recently announced its second quarter dividends for 2025, detailing robust financial strategies and growth, as reflected in the declared dividends on Class B-2 activity-based capital stock and Class B-1 non-activity-based stock. These dividends have been set at annualized rates of 9.50% and 4.50%,...

Continue Reading
Neurogen Biomarking Partners with Quanterix for Alzheimer's Testing

Updated Category News Views 255

Revolutionizing Alzheimer's Detection with Neurogen Biomarking Neurogen Biomarking is making significant strides in the healthcare landscape by introducing a pioneering blood test aimed at the early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). This innovative approach leverages advanced biomarker technology developed by Quanterix Corporation,...

Continue Reading
Kepler Robotics Launches Innovative Humanoid Robot for Industries

Updated Category News Views 296

Revolutionizing Industries with the K2 Bumblebee Shanghai Kepler Robotics Co., Ltd has excitedly announced the commencement of mass production of its K2 "Bumblebee" model, confirming that the world's first commercially available hybrid-architecture humanoid robot is now shipping to eager customers. Milestone in Humanoid Robotics This significant development not only marks...

Continue Reading
Syntara Limited Reveals Groundbreaking Data in Myelofibrosis Trials

Updated Category News Views 259

Positive Interim Data from Syntara's Clinical Trials Syntara Limited, known for its innovative approach in drug development, has unveiled promising interim data concerning its ongoing Phase 2 study of SNT-5505. This clinical trial focuses on myelofibrosis, a complex bone marrow disorder that often leads to severe health complications. Details of the Clinical Trial The...

Continue Reading